Genomic analysis to guide choice of treatment for smoking cessation

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  David, Sean P ^a   Bergen, Andrew W ^b   Munafò, Marcus R ^c   Schuit, Ewoud ^d   Bennett, Derrick A ^e   Panagiotou, Orestis A ^f  

^a STANFORD UNIVERSITY   (United States)

^b SRI INTERNATIONAL   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTISINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; NORTRIPTYLINE; VARENICLINE;

ARTICLE; DNA DETERMINATION; GENETIC ANALYSIS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

EID: 85041742535     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011823     Document Type: Article

References (62)

1. Agrawal A, Verweij KJ, Gillespie NA, Heath AC, Lessov-Schlaggar CN, Martin NG, et al. The genetics of addiction-a translational perspective. Translational Psychiatry 2012;2(e140):1-14. [PUBMED: 22806211]
2. Balfour DJ. The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handbook of Experimental Pharmacology 2009;192:209-33. [PUBMED: 19184651]
3. Benowitz NL, Swan GE, Jacob P 3rd, Lessov-Schlaggar CN, Tyndale RF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clinical Pharmacology and Therapeutics 2006;80(5):457-67. [PUBMED: 17112802]
4. Benowitz NL, Hukkanen J, Jacob P 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handbook of Experimental Pharmacology 2009;192:29-60. [PUBMED: 19184645]
5. Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, Jacob P 3rd. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenetics and Genomics 2013;23(3):135-41. [PUBMED: 23344581]
6. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics 2013;23(2):94-103. [PUBMED: 23249876]
7. Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. Nicotine & Tobacco Research 2014;16(12):1638-46. [PUBMED: 25143296]
8. Bloom AJ, Harari O, Martinez M, Madden PA, Martin NG, Montgomery GW, et al. Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. Human Molecular Genetics 2012;21(13):3050-62. [PUBMED: 22451501]
9. Broms U, Silventoinen K, Madden PA, Heath AC, Kaprio J. Genetic architecture of smoking behavior: a study of Finnish adult twins. Twin Research and Human Genetics 2006;9(1):64-72. [PUBMED: 16611469]
10. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD006103.pub6; PUBMED: 22513936]
11. Canova C, Hashibe M, Simonato L, Nelis M, Metspalu A, Lagiou P, et al. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Research 2009;69(7):2956-65. [PUBMED: 19339270]
12. Carmelli D, Swan GE. Genetic influence on smoking--a study of male twins. New England Journal of Medicine 1992;327(12):829-33. [PUBMED: 1508241]
13. Chen LS, Baker TB, Piper ME, Breslau N, Cannon DS, Doheny KF, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. American Journal of Psychiatry 2012;169(7):735-42. [PUBMED: 22648373]
14. Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction 2014;109(1):128-37. [PUBMED: 24033696]
15. David SP, Johnstone EC, Murphy MF, Aveyard P, Guo B, Lerman C, et al. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug and Alcohol Dependence 2008;98(1-2):77-85. [PUBMED: 18562131]
16. David SP, Hamidovic A, Chen GK, Bergen AW, Wessel J, Kasberger JL, et al. Genome-wide meta-analyses of smoking behaviors in African Americans. Translational Psychiatry 2012;2:e119. [PUBMED: 22832964 ]
17. Fisher RA. Lung cancer and cigarettes?. Nature 1958;182(4628):108. [PUBMED: 13566198]
18. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ. Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature 2011;471(7340):597-601. [PUBMED: 21278726]
19. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004;25(12):2451-8. [PUBMED: 15308589]
20. Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 2007;28(6):1287-93. [PUBMED: 17259654]
21. Giovino GA, Mirza SA, Samet JM, Gupta PC, Jarvis MJ, Bhala N, et al. GATS Collaborative Group. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. Lancet 2012;380(9842):668-79. [PUBMED: 22901888]
22. Hadjiconstantinou M, Neff NH. Nicotine and endogenous opioids: neurochemical and pharmacological evidence. Neuropharmacology 2011 Jun;60(7-8):1209-20. [PUBMED: 21108953]
23. Heath AC, Martin NG, Lynskey MT, Todorov AA, Madden PA. Estimating two-stage models for genetic influences on alcohol, tobacco or drug use initiation and dependence vulnerability in twin and family data. Twin Research 2002;5(2):113-24. [PUBMED: 11931689]
24. Herman AI, DeVito EE, Jensen KP, Sofuoglu M. Pharmacogenetics of nicotine addiction: role of dopamine. Pharmacogenomics 2014;15(2):221-34. [PUBMED: 24444411]
25. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
27. Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clinical Pharmacology and Therapeutics 2009;85(6):635-43. [PUBMED: 19279561]
28. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD000031.pub4; PUBMED: 24402784]
29. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 2012;37(3):641-50. [PUBMED: 22048466]
30. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clinical Pharmacology and Therapeutics 2006;79(6):600-8. [PUBMED: 16765148]
31. Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clinical Pharmacology and Therapeutics 2010;87(5):553-7. [PUBMED: 20336063]
32. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003;98(1):23-31. [PUBMED: 12492752]
33. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nature Genetics 2010;42(5):436-40. [PUBMED: 20418889]
34. Liu T, David SP, Tyndale RF, Wang H, Zhou Q, Ding P, et al. Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction 2011;106(5):985-94. [PUBMED: 21205058]
35. Marteau TM, Aveyard P, Munafò MR, Prevost AT, Hollands GJ, Armstrong D, et al. Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial. PLoS One 2012;7(4):e35249. [PUBMED: 22509402]
36. McCaffery JM, Papandonatos GD, Lyons MJ, Koenen KC, Tsuang MT, Niaura R. Educational attainment, smoking initiation and lifetime nicotine dependence among male Vietnam-era twins. Psychological Medicine 2008;38(9):1287-97. [PUBMED: 17949517]
37. McDonagh EM, Wassenaar C, David SP, Tyndale RF, Altman RB, Whirl-Carrillo M, et al. PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenetics and Genomics 2012;22(9):695-708. [PUBMED: 22547082]
38. Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Association of the mu-opioid receptor gene with smoking cessation [Association of the mu-opioid receptor gene with smoking cessation]. Pharmacogenomics J. 2007 Oct;7(5):353-61. [17224915]
39. Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine & Tobacco Research 2011;13(10):982-8. [PUBMED: 21690317]
40. Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clinical Pharmacology and Therapeutics 2008;84(3):320-5. [PUBMED: 18388868]
41. Quaak M, Van Schayck CP, Postma DS, Wagena EJ, Van Schooten FJ. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Addiction 2012;107(1):178-87. [PUBMED: 21658141]
42. Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, et al. Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine & Tobacco Research 2007;9(11):1237-41. [PUBMED: 17978999]
43. Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM, et al. Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PLoS One 2009;4(5):e5652. [PUBMED: 19479063]
44. Saccone NL, Culverhouse RC, Schwantes-An TH, Cannon DS, Chen X, Cichon S, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genetics 2010;6(8):e1001053. [PUBMED: 20700436]
45. Scherf DB, Sarkisyan N, Jacobsson H, Claus R, Bermejo JL, Peil B, et al. Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4. Oncogene 2012;32(28):3329-38. [PUBMED: 22945651]
46. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacology, Biochemistry, and Behavior 2009;92(1):6-11. [PUBMED: 19000709]
47. Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Annals of Internal Medicine 2010;152(3):144-51. [PUBMED: 20124230]
48. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult caucasians. Pharmacogenetics 2004;14(9):615-26. [PUBMED: 15475735]
49. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD000146.pub4; PUBMED: 23152200]
50. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD009670.pub2; PUBMED: 23235680]
51. Sullivan PF, Neale BM, Van den Oord E, Miles MF, Neale MC, Bulik CM, et al. Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics. American Journal of Medical Genetics: Part B Neuropsychiatric Genetics 2004;126B(1):23-36. [PUBMED: 15048644]
52. Tamaki Y, Arai T, Sugimura H, Sasaki T, Honda M, Muroi Y, et al. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metabolism and Pharmacokinetics 2011;26(5):516-22. [PUBMED: 21791872]
53. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452(7187):638-42. [PUBMED: 18385739]
54. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nature Genetics 2010;42(5):448-53. [PUBMED: 20418888]
55. Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nature Genetics 2010;42(5):441-7. [PUBMED: 20418890]
56. Topcu Z, Chiba I, Fujieda M, Shibata T, Ariyoshi N, Yamazaki H, et al. CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. Carcinogenesis 2002;23(4):595-8. [PUBMED: 11960911]
57. True WR, Heath AC, Scherrer JF, Waterman B, Goldberg J, Lin N, et al. Genetic and environmental contributions to smoking. Addiction 1997;92(10):1277-87. [PUBMED: 9489045]
58. Verhagen M, Kleinjan M, Engels RC. A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. Pharmacogenomics 2013;13(8):917-33. [PUBMED: 22676196]
59. Wang J, Li MD. Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology 2010;35(3):702-19. [PUBMED: 19890259]
60. Ware JJ, Van den Bree M, Munafò MR. From men to mice: CHRNA5/CHRNA3, smoking behavior and disease. Nicotine & Tobacco Research 2012;14(11):1291-9. [PUBMED: 22544838]
61. Xian H, Scherrer JF, Grant JD, Eisen SA, True WR, Jacob T, et al. Genetic and environmental contributions to nicotine, alcohol and cannabis dependence in male twins. Addiction 2008;103(8):1391-8. [PUBMED: 18855830]
62. Zhu AZ, Zhou Q, Cox LS, David SP, Ahluwalia JS, Benowitz NL, et al. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African American smokers. Clinical Pharmacology and Therapeutics 2014;96(2):256-65. [PUBMED: 24733007]